Bharat Immunological & Biological Corporation Ltd
Established in 1989, Bharat Immunological and Biologicals Corporation is a Govt. of India Undertaking biotechnology company. Company is engaged in the manufacture of Oral polio Vaccine, Zinc Tablets, Diarrhea management Kit and BIB Sweet Tablets
- Market Cap ₹ 108 Cr.
- Current Price ₹ 25.0
- High / Low ₹ 43.9 / 22.2
- Stock P/E
- Book Value ₹ 18.2
- Dividend Yield 0.00 %
- ROCE -9.27 %
- ROE -17.7 %
- Face Value ₹ 10.0
Pros
- Company's working capital requirements have reduced from 34.4 days to 25.4 days
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 5.09% over past five years.
- Company has a low return on equity of -22.7% over last 3 years.
- Debtor days have increased from 39.6 to 114 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Part of BSE CPSE
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
46 | 173 | 203 | 146 | 128 | 124 | 35 | 84 | 67 | 85 | 78 | 45 | 8 | |
41 | 164 | 191 | 143 | 132 | 111 | 43 | 93 | 77 | 106 | 83 | 63 | 25 | |
Operating Profit | 6 | 9 | 12 | 3 | -4 | 13 | -8 | -9 | -10 | -21 | -5 | -18 | -18 |
OPM % | 12% | 5% | 6% | 2% | -3% | 10% | -23% | -11% | -16% | -24% | -6% | -41% | -232% |
2 | 1 | 6 | 1 | 1 | 1 | 1 | 4 | 1 | 2 | 1 | 3 | 1 | |
Interest | 0 | 2 | 6 | 1 | 6 | 4 | 1 | 2 | 5 | 5 | 6 | 7 | 8 |
Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit before tax | 6 | 7 | 11 | 2 | -9 | 9 | -8 | -7 | -14 | -24 | -10 | -23 | -25 |
Tax % | -111% | 27% | 42% | 26% | -31% | 29% | -46% | -21% | -28% | -25% | -10% | -25% | |
13 | 5 | 6 | 2 | -6 | 7 | -4 | -6 | -10 | -18 | -9 | -17 | -18 | |
EPS in Rs | 2.91 | 1.16 | 1.48 | 0.36 | -1.44 | 1.51 | -0.99 | -1.34 | -2.36 | -4.19 | -2.03 | -3.95 | -4.18 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | -13% |
5 Years: | 5% |
3 Years: | -13% |
TTM: | -90% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -31% |
TTM: | -42% |
Stock Price CAGR | |
---|---|
10 Years: | -4% |
5 Years: | 28% |
3 Years: | -19% |
1 Year: | -4% |
Return on Equity | |
---|---|
10 Years: | -12% |
5 Years: | -24% |
3 Years: | -23% |
Last Year: | -18% |
Balance Sheet
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 |
Reserves | -15 | -1 | -3 | -2 | -8 | -1 | -6 | -12 | -23 | -9 | 62 | 45 | 36 |
7 | 0 | -1 | -9 | 9 | 0 | 0 | 32 | 3 | 27 | 78 | 70 | 74 | |
45 | 48 | 52 | 48 | 24 | 17 | 16 | 62 | 103 | 43 | 29 | 28 | 35 | |
Total Liabilities | 81 | 90 | 91 | 80 | 68 | 59 | 53 | 125 | 127 | 104 | 213 | 186 | 188 |
9 | 8 | 7 | 6 | 6 | 5 | 5 | 5 | 4 | 4 | 116 | 115 | 115 | |
CWIP | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 32 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
71 | 82 | 84 | 74 | 63 | 53 | 48 | 120 | 122 | 68 | 97 | 70 | 73 | |
Total Assets | 81 | 90 | 91 | 80 | 68 | 59 | 53 | 125 | 127 | 104 | 213 | 186 | 188 |
Cash Flows
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
5 | 31 | -12 | 8 | -9 | -17 | 3 | -32 | 34 | 12 | -42 | 11 | |
-0 | 0 | 0 | 0 | 1 | 0 | -1 | 1 | 1 | 1 | 1 | 0 | |
-3 | -0 | -6 | -1 | -2 | -3 | -1 | 31 | -34 | -12 | 45 | -15 | |
Net Cash Flow | 2 | 31 | -18 | 7 | -10 | -20 | 1 | -1 | 1 | 0 | 3 | -3 |
Ratios
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 209 | 2 | 47 | 34 | 37 | 19 | 167 | 318 | 96 | 0 | 5 | 114 |
Inventory Days | 241 | 87 | 66 | 84 | 77 | 2 | 23 | 67 | 308 | 56 | 202 | 13 |
Days Payable | 316 | 99 | 70 | 103 | 26 | 1 | 6 | 204 | 259 | 61 | 5 | 4 |
Cash Conversion Cycle | 134 | -9 | 43 | 16 | 88 | 19 | 185 | 181 | 145 | -5 | 203 | 122 |
Working Capital Days | 34 | -20 | 19 | -2 | 55 | -19 | 59 | 151 | -91 | -57 | 135 | 25 |
ROCE % | 20% | 23% | 42% | 9% | -8% | 31% | -18% | -11% | -22% | -46% | -3% | -9% |
Documents
Announcements
-
Board Meeting Intimation for Intimation Of Date Of Board Meeting On 16.08.2024 Under Regulation 29 Of SEBI'S LODR.
7 Aug - Board meeting scheduled for August 16, 2024.
-
Board Meeting Intimation for Intimation Of Date Of Board Meeting On 08.03.2024 Under Regulation 29 Of SEBI'S LODR.
29 Feb - Board meeting scheduled for March 8, 2024.
- Compliance Of Regulation 34 Of LODR 2015 And Submission Annual Report For 34Th Annual General Meeting Scheduled On 29.12.2023. 13 Dec 2023
- Compliance Of The Regulation Of LODR 2015 For The Intimation Of Book Closure Period (22.12.2023 To 29.12.2023) Of The Company In Respect Of 34Th Annual General Meeting Scheduled To Be Held On 29.12.2023. 28 Nov 2023
- Submission Of Notice Of 34Th Annual General Meeting On 29.12.2023 As Compliance Of The Provision Of LODR 2015. 28 Nov 2023
Annual reports
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
-
Financial Year 2008
from bse
Product Portfolio:
a) (OPV) Polio Vaccines[1]
b) Bibcol Sanitizers[2]
c) BIB Sweet Tab[3]
d) BIBCOL BIBVIT Immunity Booster Tablet[4]
e) BIB Zinc 20mg and ORS[5][6]